INR:6014. lottery sambad 8 00 baje ka Rubraca significantly prolongs progression-free survival in phase 3 clinical trial of BRCA-mutated ovarian cance ...

shg report Ono Pharmaceutical's triple therapy for non-squamous lung cancer is successful in Phase III: significantly prolonging progression-free survival Phase II proof-of-concept study is successful ...

Fire DG Name Ono Pharmaceutical's triple therapy for non-squamous lung cancer is successful in Phase III: significantly prolonging progression-free surviva ...

Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

As part of its end-of-the-year celebrations, Dead by Daylight reveals codes that let players claim various in-game items and ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

This page includes links to articles highlighting the top gastrointestinal cancer research published on Cancer Therapy ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

And from the looks of it, the future certainly seems bright, with firm release dates set for major titles such as Assassin’s ...